Lord, Abbett & Co. LLC Intra Cellular Therapies, Inc. Transaction History

Lord, Abbett & Co. LLC

$30.6 Billion
Q2 2024

A detailed history of Lord, Abbett & Co. LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 633,458 shares of ITCI stock, worth $54.8 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

633,458

Previous 472,687 34.01%

Holding current value

$54.8 Million

Previous $32.7 Million 32.64%

% of portfolio

0.14%

Previous 0.11%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 07, 2024	BUY	$64.76 - $79.84 $10.4 Million - $12.8 Million	160,771 Added 34.01%	633,458 $43.4 Million
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $10.4 Million - $12.8 Million	160,771 Added 34.01%	633,458 $43.4 Million
Q1 2024 Oct 07, 2024	SELL	$64.37 - $75.65 $19.3 Million - $22.7 Million	-300,280 Reduced 38.85%	472,687 $32.7 Million
Q1 2024 May 09, 2024	SELL	$64.37 - $75.65 $19.3 Million - $22.7 Million	-300,280 Reduced 38.85%	472,687 $32.7 Million
Q4 2023 Oct 07, 2024	BUY	$46.37 - $73.65 $5.61 Million - $8.91 Million	120,937 Added 18.55%	772,967 $55.4 Million
Q4 2023 Feb 12, 2024	BUY	$46.37 - $73.65 $5.61 Million - $8.91 Million	120,937 Added 18.55%	772,967 $55.4 Million
Q3 2023 Oct 07, 2024	SELL	$52.09 - $64.1 $33.4 Million - $41.1 Million	-640,738 Reduced 49.56%	652,030 $34 Million
Q3 2023 Nov 13, 2023	SELL	$52.09 - $64.1 $33.4 Million - $41.1 Million	-640,738 Reduced 49.56%	652,030 $34 Million
Q2 2023 Oct 07, 2024	BUY	$54.67 - $66.44 $32.2 Million - $39.1 Million	588,837 Added 83.65%	1,292,768 $81.9 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $32.2 Million - $39.1 Million	588,837 Added 83.65%	1,292,768 $81.9 Million
Q1 2023 Oct 07, 2024	SELL	$43.8 - $56.99 $8.03 Million - $10.5 Million	-183,442 Reduced 20.67%	703,931 $38.1 Million
Q1 2023 May 12, 2023	SELL	$43.8 - $56.99 $8.03 Million - $10.5 Million	-183,442 Reduced 20.67%	703,931 $38.1 Million
Q4 2022 Oct 07, 2024	BUY	$44.07 - $54.45 $11.2 Million - $13.8 Million	253,915 Added 40.08%	887,373 $47 Million
Q4 2022 Feb 10, 2023	SELL	$44.07 - $54.45 $49.9 Million - $61.6 Million	-1,131,313 Reduced 56.04%	887,373 $47 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $7.16 Million - $10.1 Million	167,737 Added 9.06%	2,018,686 $93.9 Million
Q2 2022 Aug 12, 2022	SELL	$43.0 - $65.64 $5.61 Million - $8.56 Million	-130,407 Reduced 6.58%	1,850,949 $106 Million
Q1 2022 May 13, 2022	SELL	$38.74 - $62.09 $5.79 Million - $9.28 Million	-149,464 Reduced 7.01%	1,981,356 $121 Million
Q4 2021 Feb 11, 2022	BUY	$35.2 - $53.42 $1.51 Million - $2.29 Million	42,786 Added 2.05%	2,130,820 $112 Million
Q3 2021 Nov 09, 2021	SELL	$28.72 - $42.49 $1.65 Million - $2.45 Million	-57,554 Reduced 2.68%	2,088,034 $77.8 Million
Q2 2021 Aug 11, 2021	BUY	$29.3 - $44.5 $687,026 - $1.04 Million	23,448 Added 1.1%	2,145,588 $87.6 Million
Q1 2021 May 11, 2021	BUY	$30.8 - $39.51 $65.4 Million - $83.8 Million	2,122,140 New	2,122,140 $72 Million

Others Institutions Holding ITCI

# of Institutions

398

Shares Held

87.5M

Call Options Held

309K

Put Options Held

302K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.17B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Account

Lord, Abbett & Co. LLC Intra Cellular Therapies, Inc. Transaction History